BioAtla Files 8-K: Other Events

TL;DR

BioAtla filed a routine 8-K for 'Other Events' on 5/15/24. No major news.

AI Summary

BioAtla, Inc. filed an 8-K on May 17, 2024, reporting an event that occurred on May 15, 2024. The filing is categorized under 'Other Events' and does not specify any material agreements, acquisitions, or executive changes, suggesting a routine or administrative update.

Why It Matters

This filing indicates a routine update or administrative event for BioAtla, Inc., which may not contain significant new information for investors.

Risk Assessment

Risk Level: low — The filing is categorized as 'Other Events' and does not disclose any material changes, agreements, or financial events, indicating a low immediate risk.

Key Players & Entities

• BioAtla, Inc. (company) — Registrant
• May 15, 2024 (date) — Date of earliest event reported
• May 17, 2024 (date) — Date of report
• 11085 Torreyana Road, San Diego, California 92121 (location) — Principal Executive Offices

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share BCAB Nasdaq Glo
• $350,000 — The Company subsequently agreed to pay $350,000 in attorneys' fees and expenses in full

Filing Documents

• bcab-20240515.htm (8-K) — 37KB
• 0000950170-24-061616.txt ( ) — 144KB
• bcab-20240515.xsd (EX-101.SCH) — 23KB
• bcab-20240515_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events. On February 6, 2024, Plaintiff Upendar Golla ("Plaintiff"), on behalf of a putative class of stockholders of Nominal Defendant BioAtla, Inc. (the "Company"), filed a Verified Class Action Complaint, in the Court of Chancery of the State of Delaware (the "Action"), alleging that the directors of the Company breached their fiduciary duties by adopting amended and restated bylaws of the Company on January 5, 2024, which were alleged to impose unreasonable disclosure and informational requirements on parties nominating a dissident director. On April 22, 2024, the Company modified the challenged provisions by amending and restating the Amended and Restated Bylaws of the Company in the form filed as Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the United States Securities and Exchange Commission (the "Commission") on April 24, 2024 (the "Reforms"). The Company denies and continues to deny all allegations of wrongdoing in the Action. Plaintiff and the Company agreed that the Reforms rendered Plaintiff's claims moot. The Company subsequently agreed to pay $350,000 in attorneys' fees and expenses in full satisfaction of any and all claims by Plaintiff and his counsel for fees and expenses in the Action. In making this decision, the Company considered various factors, including the cost and time associated with litigation. On May 15, 2024, the Court entered an order closing the Action, subject to the Company filing an affidavit with the Court confirming that this Current Report on Form 8-K, which shall constitute notice to the putative class for purposes of Rule 23, has been filed with the Commission. Plaintiff's counsel are Ned Weinberger and Brendan W. Sullivan of Labaton Keller Sucharow LLP, (302) 573-2540. Defendants' counsel are D. McKinley Measley and Grant E. Michl of Morris, Nichols, Arsht & Tunnell LLP, (302) 658-9200.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioAtla, Inc. Date: May 17, 2024 By: /s/ Richard Waldron Richard Waldron Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR